Christian Matek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christian Matek has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Markus Eckstein
Department of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
4 shared publications Arndt Hartmann
Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Cancer Research Center (BZKF), Erlangen, Germany; Comprehensive Cancer Centre WERA (CCC WERA), Germany
3 shared publications- Arndt Hartmann
Institute of Pathology University Hospital Erlangen, Friedrich‐Alexander‐Universität Erlangen‐Nürnberg (FAU) Erlangen Germany
3 shared publications - Carsten Marr
Computational Health Center & Helmholtz AI, Helmholtz Munich, Neuherberg, Germany
3 shared publications - Felix Elsner
Institut für Pathologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Deutschland
3 shared publications - Konrad Steinestel
Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, 89081 Ulm, Germany
3 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Wiley in The Journal of Pathology
Beyond a single ratio: an adaptable deep learning approach to analyze the prognostic value of TSP distribution in ovarian cancer
The tumor–stroma percentage (TSP) has been proposed as a prognostic factor in ovarian cancer. When assessed manually by pathologists, the TSP can be subject to significant inter‐rater variability. Automated methods for TSP determination have recently been developed. Existing approaches typically yield a single TSP value for a relatively small region of interest in the slide, introducing bias through region selection and potentially overlooking the TSP distribution across the entire histologically examined area. We present an adaptable deep learning pipeline, efficiently fine‐tuned for ovarian cancer tissue analysis using a few‐shot learning approach, requiring only minimal new training annotations. Instead of calculating a single TSP value, our method quantifies the global TSP distribution across the entire tumor and therefore captures its spatial heterogeneity. To identify a prognostic biomarker, we systematically evaluated a panel of metrics describing this distribution in 98 patients. Our analysis revealed that the mean–median difference of the TSP distribution [hazard ratio (HR) = 0.60, 95% CI = 0.46–0.79, p < 0.001], a quantitative measure of asymmetry, together with the mean TSP (HR = 0.65, 95% CI = 0.43–0.97, p = 0.03), are biomarkers significantly associated with recurrence‐free survival. By successfully adapting a pipeline for ovarian cancer, we demonstrate that automated analysis of the entire TSP distribution provides significant prognostic information superior to that obtained by manual assessment. Spatial heterogeneity of the TSP is a key prognostic factor. © 2026 Fraunhofer IIS and The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 27 October 2026
- Published by Wiley in The Journal of Pathology
Open AccessBeyond a single ratio: an adaptable deep learning approach to analyze the prognostic value of TSP distribution in ovarian cancer
The tumor–stroma percentage (TSP) has been proposed as a prognostic factor in ovarian cancer. When assessed manually by pathologists, the TSP can be subject to significant inter‐rater variability. Automated methods for TSP determination have recently been developed. Existing approaches typically yield a single TSP value for a relatively small region of interest in the slide, introducing bias through region selection and potentially overlooking the TSP distribution across the entire histologically examined area. We present an adaptable deep learning pipeline, efficiently fine‐tuned for ovarian cancer tissue analysis using a few‐shot learning approach, requiring only minimal new training annotations. Instead of calculating a single TSP value, our method quantifies the global TSP distribution across the entire tumor and therefore captures its spatial heterogeneity. To identify a prognostic biomarker, we systematically evaluated a panel of metrics describing this distribution in 98 patients. Our analysis revealed that the mean–median difference of the TSP distribution [hazard ratio (HR) = 0.60, 95% CI = 0.46–0.79, p < 0.001], a quantitative measure of asymmetry, together with the mean TSP (HR = 0.65, 95% CI = 0.43–0.97, p = 0.03), are biomarkers significantly associated with recurrence‐free survival. By successfully adapting a pipeline for ovarian cancer, we demonstrate that automated analysis of the entire TSP distribution provides significant prognostic information superior to that obtained by manual assessment. Spatial heterogeneity of the TSP is a key prognostic factor. © 2026 Fraunhofer IIS and The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- Open Access
- 10 September 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 247, 117035
Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma
- 10 September 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 247, 117035
Open AccessDirect Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma
- Open Access
- 28 July 2026
- Published by Elsevier in SSRN Electronic Journal
Artificial Intelligence–Based Assessment of Pathologic Response to Neoadjuvant Chemoimmunotherapy in Non–Small Cell Lung Cancer: An International Multicenter Cohort Study
BackgroundPathologic response (PR), expressed as the percentage of residual viable tumor (%RVT), has emerged as a surrogate endpoint after neoadjuvant chemoimmunotherapy in non–small cell lung cancer (NSCLC). However, PR assessment remains subject to interobserver variability and is insufficiently standardized across institutions and clinical trials. We hypothesized that artificial intelligence (AI)-based %RVT scoring would be concordant with expert manual assessment and consistent across real-world, multi-scanner cohorts.Materials and methodsFour retrospective NSCLC cohorts treated with neoadjuvant chemoimmunotherapy and surgery were analyzed. The internal cohort included 38 patients; three external cohorts from China, Germany, and Spain contributed 97 additional patients. Weighted consensus manual %RVT served as the reference standard for benchmarking an AI algorithm. Discordant cases were interrogated for algorithmic bias.ResultsOverall, 135 patients and 1,344 primary-tumor H&E slides were evaluable. Concordance between AI-based and manual assessment was at least moderate across all cohorts. For major pathologic response (MPR) classification, the AI algorithm achieved a pooled accuracy of 91% (95% CI, 85–95), sensitivity of 90% (82–95), specificity of 93% (81–99), and an area under the curve ≥0.95 in all cohorts. Discordant classifications occurred in 8.9% of cases and were mainly attributable to stromal underrepresentation and misclassification of non-neoplastic elements.ConclusionsAI-based %RVT scoring was concordant with expert pathologist consensus and consistent across real-world, multicenter, multi-scanner cohorts, with most algorithmic errors mirroring those encountered in human practice. By providing explainable %RVT grounded in international recommendations, our framework may facilitate harmonization of PR assessment for perioperative therapies.
- 28 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessArtificial Intelligence–Based Assessment of Pathologic Response to Neoadjuvant Chemoimmunotherapy in Non–Small Cell Lung Cancer: An International Multicenter Cohort Study
BackgroundPathologic response (PR), expressed as the percentage of residual viable tumor (%RVT), has emerged as a surrogate endpoint after neoadjuvant chemoimmunotherapy in non–small cell lung cancer (NSCLC). However, PR assessment remains subject to interobserver variability and is insufficiently standardized across institutions and clinical trials. We hypothesized that artificial intelligence (AI)-based %RVT scoring would be concordant with expert manual assessment and consistent across real-world, multi-scanner cohorts.Materials and methodsFour retrospective NSCLC cohorts treated with neoadjuvant chemoimmunotherapy and surgery were analyzed. The internal cohort included 38 patients; three external cohorts from China, Germany, and Spain contributed 97 additional patients. Weighted consensus manual %RVT served as the reference standard for benchmarking an AI algorithm. Discordant cases were interrogated for algorithmic bias.ResultsOverall, 135 patients and 1,344 primary-tumor H&E slides were evaluable. Concordance between AI-based and manual assessment was at least moderate across all cohorts. For major pathologic response (MPR) classification, the AI algorithm achieved a pooled accuracy of 91% (95% CI, 85–95), sensitivity of 90% (82–95), specificity of 93% (81–99), and an area under the curve ≥0.95 in all cohorts. Discordant classifications occurred in 8.9% of cases and were mainly attributable to stromal underrepresentation and misclassification of non-neoplastic elements.ConclusionsAI-based %RVT scoring was concordant with expert pathologist consensus and consistent across real-world, multicenter, multi-scanner cohorts, with most algorithmic errors mirroring those encountered in human practice. By providing explainable %RVT grounded in international recommendations, our framework may facilitate harmonization of PR assessment for perioperative therapies.
- Open Access
- 26 June 2026
- Published by Elsevier in Lung Cancer
- Vol. 218, 109510
Limited predictive value of PD-L1 TPS for pathological response in NSCLC is not attributable to interobserver variability
- 26 June 2026
- Published by Elsevier in Lung Cancer
- Vol. 218, 109510
Open AccessLimited predictive value of PD-L1 TPS for pathological response in NSCLC is not attributable to interobserver variability
- Open Access
- 6 June 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1) , 205
AI-assisted histomorphological stratification of endometrial cancer: real-world validation of foundation models for molecular subtyping
Endometrial cancer (EC) is classified into four molecular subtypes with distinct prognosis and treatment implications. Despite this well-established molecular classification, morpho-molecular correlations remain understudied. Artificial intelligence (AI) enables biomarker prediction from H&E-stained whole-slide images (WSIs). However, real-world validation for EC molecular subtyping is lacking. In this study, we evaluated image-based molecular subtyping in a real-world cohort derived from routine diagnostic cases with heterogeneous image quality. We benchmarked the feature extraction with the CTransPath and UNI foundation models, demonstrating robust results across different scanner hardware and quantified performance variation by additional stain normalization. UNI-based features achieved a mean AUROC of 0.646 for POLE mut ( n = 16), 0.700 for MMRd_MSI ( n = 79), 0.684 for NSMP ( n = 176), and 0.844 for p53abn ( n = 18) on external real-world data. We provided human interpretations of subtype-specific morphological features. Our findings may thus lay the foundations of a more reliable framework for personalized treatment stratification based on morphologically informed molecular subtyping.
- 6 June 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1) , 205
Open AccessAI-assisted histomorphological stratification of endometrial cancer: real-world validation of foundation models for molecular subtyping
Endometrial cancer (EC) is classified into four molecular subtypes with distinct prognosis and treatment implications. Despite this well-established molecular classification, morpho-molecular correlations remain understudied. Artificial intelligence (AI) enables biomarker prediction from H&E-stained whole-slide images (WSIs). However, real-world validation for EC molecular subtyping is lacking. In this study, we evaluated image-based molecular subtyping in a real-world cohort derived from routine diagnostic cases with heterogeneous image quality. We benchmarked the feature extraction with the CTransPath and UNI foundation models, demonstrating robust results across different scanner hardware and quantified performance variation by additional stain normalization. UNI-based features achieved a mean AUROC of 0.646 for POLE mut ( n = 16), 0.700 for MMRd_MSI ( n = 79), 0.684 for NSMP ( n = 176), and 0.844 for p53abn ( n = 18) on external real-world data. We provided human interpretations of subtype-specific morphological features. Our findings may thus lay the foundations of a more reliable framework for personalized treatment stratification based on morphologically informed molecular subtyping.
- Open Access
- 7 May 2026
- Published by Elsevier in Expert Systems with Applications
- Vol. 327
Hierarchical supervision in DINOv2 training improves generalizability on white blood cell images
- 7 May 2026
- Published by Elsevier in Expert Systems with Applications
- Vol. 327
Open AccessHierarchical supervision in DINOv2 training improves generalizability on white blood cell images
- Open Access
- 5 September 2025
- Published by Wiley in Histopathology
- Vol. 87 (6) , 869-879
Current practice of pathologic response assessment following chemoimmunotherapy for non‐small cell lung cancer ( NSCLC ) in Germany: first real‐world data from the multicentre Re‐ GraDE study
Background: Given that pathologists now frequently assess pathologic response following neoadjuvant or perioperative chemoimmunotherapy for NSCLC, we set up a multicentre study to evaluate the current practice of re gression gra ding in Germany (Re‐GraDE NSCLC). Methods: 133 cases of NSCLC resection specimens following chemoimmunotherapy (IO) were collected from 9 high‐volume lung cancer centres in Germany. Case characteristics were obtained from pathology reports/electronic medical records. In 107 cases, pretreatment biopsies were available on‐site. Results: Residual viable tumour (% RVT) was commonly used to measure therapy response (106/133 resection specimens, 79.7%). The entire tumour bed was submitted for histology in 55.6% of cases; however, in 18%, a tumour bed of ≤3 cm was not completely submitted. Either Junker or IASLC regression grading was applied in 97.7% of primary tumours and 60.2% of lymph nodes with comparable results. Almost half of the tumours (45.9%) showed pathological complete response (pCR and/or regression grade (RG) III) with a very weak correlation between % RVT and pretreatment PD‐L1 TPS ( r 2 = 0.078, P = 0.007). Pretreatment PD‐L1 levels ranged from 0% to 100% (median, 60%) in cases with complete regression, and pCR was observed in 40% of cases with pretreatment PD‐L1 TPS <1%. Conclusions: Our multicentre study describes the current practice of histopathological regression grading of NSCLC after IO in Germany, highlighting the widespread use of the Junker system, which is basically comparable to IASLC regression grading. For standardization, we recommend following the IASLC guidelines (submitting of the complete tumour bed if ≤3 cm), while the reporting of % RVT might represent a continuous parameter for therapy response. Our digital nationwide registry, which aims to integrate biopsy results, molecular profiling and % RVT in resection specimens, might develop into a valuable tool to investigate novel predictive biomarkers of IO efficacy.
- 5 September 2025
- Published by Wiley in Histopathology
- Vol. 87 (6) , 869-879
Open AccessCurrent practice of pathologic response assessment following chemoimmunotherapy for non‐small cell lung cancer ( NSCLC ) in Germany: first real‐world data from the multicentre Re‐ GraDE study
Background: Given that pathologists now frequently assess pathologic response following neoadjuvant or perioperative chemoimmunotherapy for NSCLC, we set up a multicentre study to evaluate the current practice of re gression gra ding in Germany (Re‐GraDE NSCLC). Methods: 133 cases of NSCLC resection specimens following chemoimmunotherapy (IO) were collected from 9 high‐volume lung cancer centres in Germany. Case characteristics were obtained from pathology reports/electronic medical records. In 107 cases, pretreatment biopsies were available on‐site. Results: Residual viable tumour (% RVT) was commonly used to measure therapy response (106/133 resection specimens, 79.7%). The entire tumour bed was submitted for histology in 55.6% of cases; however, in 18%, a tumour bed of ≤3 cm was not completely submitted. Either Junker or IASLC regression grading was applied in 97.7% of primary tumours and 60.2% of lymph nodes with comparable results. Almost half of the tumours (45.9%) showed pathological complete response (pCR and/or regression grade (RG) III) with a very weak correlation between % RVT and pretreatment PD‐L1 TPS ( r 2 = 0.078, P = 0.007). Pretreatment PD‐L1 levels ranged from 0% to 100% (median, 60%) in cases with complete regression, and pCR was observed in 40% of cases with pretreatment PD‐L1 TPS <1%. Conclusions: Our multicentre study describes the current practice of histopathological regression grading of NSCLC after IO in Germany, highlighting the widespread use of the Junker system, which is basically comparable to IASLC regression grading. For standardization, we recommend following the IASLC guidelines (submitting of the complete tumour bed if ≤3 cm), while the reporting of % RVT might represent a continuous parameter for therapy response. Our digital nationwide registry, which aims to integrate biopsy results, molecular profiling and % RVT in resection specimens, might develop into a valuable tool to investigate novel predictive biomarkers of IO efficacy.
- Open Access
- 4 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 7163
A multimodal dataset for precision oncology in head and neck cancer
Head and neck cancer is a common disease and is associated with a poor prognosis. A promising approach to improving patient outcomes is personalized treatment, which uses information from a variety of modalities. However, only little progress has been made due to the lack of large public datasets. We present a multimodal dataset, HANCOCK, that comprises monocentric, real-world data of 763 head and neck cancer patients. Our dataset contains demographical, pathological, and blood data as well as surgery reports and histologic images, that can be explored in a low-dimensional representation. We can show that combining these modalities using machine learning is superior to a single modality and the integration of imaging data using foundation models helps in endpoint prediction. We believe that HANCOCK will not only open new insights into head and neck cancer pathology but also serve as a major source for researching multimodal machine-learning methodologies in precision oncology.
- 4 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 7163
Open AccessA multimodal dataset for precision oncology in head and neck cancer
Head and neck cancer is a common disease and is associated with a poor prognosis. A promising approach to improving patient outcomes is personalized treatment, which uses information from a variety of modalities. However, only little progress has been made due to the lack of large public datasets. We present a multimodal dataset, HANCOCK, that comprises monocentric, real-world data of 763 head and neck cancer patients. Our dataset contains demographical, pathological, and blood data as well as surgery reports and histologic images, that can be explored in a low-dimensional representation. We can show that combining these modalities using machine learning is superior to a single modality and the integration of imaging data using foundation models helps in endpoint prediction. We believe that HANCOCK will not only open new insights into head and neck cancer pathology but also serve as a major source for researching multimodal machine-learning methodologies in precision oncology.
- Open Access
A large expert-annotated single-cell peripheral blood dataset for hematological disease diagnostics
Distinguishing cell types in peripheral blood smears is critical for diagnosing blood diseases, such as leukemia subtypes. Artificial intelligence can assist in automating cell classification. For training robust machine learning algorithms, however, large and well-annotated single-cell datasets are pivotal. Here, we introduce a large, publicly available, annotated peripheral blood dataset comprising >40,000 single-cell images classified into 18 classes by cytomorphology experts from the Munich Leukemia Laboratory, the largest European laboratory for blood disease diagnostics. By making our dataset publicly available, we provide a valuable resource for medical and machine learning researchers and support the development of reliable and clinically relevant diagnostic tools for diagnosing hematological diseases.
Open AccessA large expert-annotated single-cell peripheral blood dataset for hematological disease diagnostics
Distinguishing cell types in peripheral blood smears is critical for diagnosing blood diseases, such as leukemia subtypes. Artificial intelligence can assist in automating cell classification. For training robust machine learning algorithms, however, large and well-annotated single-cell datasets are pivotal. Here, we introduce a large, publicly available, annotated peripheral blood dataset comprising >40,000 single-cell images classified into 18 classes by cytomorphology experts from the Munich Leukemia Laboratory, the largest European laboratory for blood disease diagnostics. By making our dataset publicly available, we provide a valuable resource for medical and machine learning researchers and support the development of reliable and clinically relevant diagnostic tools for diagnosing hematological diseases.
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 6 (4) , e230344
Association of Cardiac MRI–derived Aortic Stiffness with Early Stages and Progression of Heart Failure with Preserved Ejection Fraction
Purpose To investigate if aortic stiffening as detected with cardiac MRI is an early phenomenon in the development and progression of heart failure with preserved ejection fraction (HFpEF). Materials and Methods Both clinical and preclinical studies were performed. The clinical study was a secondary analysis of the prospective HFpEF stress trial (August 2017 through September 2019) and included 48 participants (median age, 69 years [range, 65-73 years]; 33 female, 15 male) with noncardiac dyspnea (NCD, n = 21), overt HFpEF at rest (pulmonary capillary wedge pressure [PCWP] ≥ 15 mm Hg, n = 14), and masked HFpEF at rest diagnosed during exercise stress (PCWP ≥ 25 mm Hg, n = 13) according to right heart catheterization. Additionally, all participants underwent echocardiography and cardiac MRI at rest and during exercise stress. Aortic pulse wave velocity (PWV) was calculated. The mechanistic preclinical study characterized cardiac function and structure in transgenic mice with induced arterial stiffness (Runx2-smTg mice). Statistical analyses comprised nonparametric and parametric comparisons, Spearman correlations, and logistic regression models. Results Participants with HFpEF showed increased PWV (NCD vs masked HFpEF: 7.0 m/sec [IQR: 5.0-9.5 m/sec] vs 10.0 m/sec [IQR: 8.0-13.4 m/sec], P = .005; NCD vs overt HFpEF: 7.0 m/sec [IQR: 5.0-9.5 m/sec] vs 11.0 m/sec [IQR: 7.5-12.0 m/sec], P = .01). Increased PWV correlated with higher PCWP (P = .006), left atrial and left ventricular long-axis strain (all P < .02), and N-terminal pro-brain natriuretic peptide levels (P < .001). Participants with overt HFpEF had higher levels of myocardial fibrosis, as demonstrated by increased native T1 times (1199 msec [IQR: 1169-1228 msec] vs 1234 msec [IQR: 1208-1255 msec], P = .009). Aortic stiffness was independently associated with HFpEF on multivariable analyses (odds ratio, 1.31; P = .049). Runx2-smTG mice exhibited an "HFpEF" phenotype compared with wild-type controls, with preserved left ventricular fractional shortening but an early and late diastolic mitral annulus velocity less than 1 (mean, 0.67 ± 0.39 [standard error of the mean] vs 1.45 ± 0.47; P = .004), increased myocardial collagen deposition (mean, 11% ± 1 vs 2% ± 1; P < .001), and increased brain natriuretic peptide levels (mean, 171 pg/mL ± 23 vs 101 pg/mL ± 10; P < .001). Conclusion This study provides translational evidence that increased arterial stiffness might be associated with development and progression of HFpEF and may facilitate its early detection. Keywords: MR Functional Imaging, MR Imaging, Animal Studies, Cardiac, Aorta, Heart ClinicalTrials.gov identifier NCT03260621 Supplemental material is available for this article. © RSNA, 2024.
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 6 (4) , e230344
Association of Cardiac MRI–derived Aortic Stiffness with Early Stages and Progression of Heart Failure with Preserved Ejection Fraction
Purpose To investigate if aortic stiffening as detected with cardiac MRI is an early phenomenon in the development and progression of heart failure with preserved ejection fraction (HFpEF). Materials and Methods Both clinical and preclinical studies were performed. The clinical study was a secondary analysis of the prospective HFpEF stress trial (August 2017 through September 2019) and included 48 participants (median age, 69 years [range, 65-73 years]; 33 female, 15 male) with noncardiac dyspnea (NCD, n = 21), overt HFpEF at rest (pulmonary capillary wedge pressure [PCWP] ≥ 15 mm Hg, n = 14), and masked HFpEF at rest diagnosed during exercise stress (PCWP ≥ 25 mm Hg, n = 13) according to right heart catheterization. Additionally, all participants underwent echocardiography and cardiac MRI at rest and during exercise stress. Aortic pulse wave velocity (PWV) was calculated. The mechanistic preclinical study characterized cardiac function and structure in transgenic mice with induced arterial stiffness (Runx2-smTg mice). Statistical analyses comprised nonparametric and parametric comparisons, Spearman correlations, and logistic regression models. Results Participants with HFpEF showed increased PWV (NCD vs masked HFpEF: 7.0 m/sec [IQR: 5.0-9.5 m/sec] vs 10.0 m/sec [IQR: 8.0-13.4 m/sec], P = .005; NCD vs overt HFpEF: 7.0 m/sec [IQR: 5.0-9.5 m/sec] vs 11.0 m/sec [IQR: 7.5-12.0 m/sec], P = .01). Increased PWV correlated with higher PCWP (P = .006), left atrial and left ventricular long-axis strain (all P < .02), and N-terminal pro-brain natriuretic peptide levels (P < .001). Participants with overt HFpEF had higher levels of myocardial fibrosis, as demonstrated by increased native T1 times (1199 msec [IQR: 1169-1228 msec] vs 1234 msec [IQR: 1208-1255 msec], P = .009). Aortic stiffness was independently associated with HFpEF on multivariable analyses (odds ratio, 1.31; P = .049). Runx2-smTG mice exhibited an "HFpEF" phenotype compared with wild-type controls, with preserved left ventricular fractional shortening but an early and late diastolic mitral annulus velocity less than 1 (mean, 0.67 ± 0.39 [standard error of the mean] vs 1.45 ± 0.47; P = .004), increased myocardial collagen deposition (mean, 11% ± 1 vs 2% ± 1; P < .001), and increased brain natriuretic peptide levels (mean, 171 pg/mL ± 23 vs 101 pg/mL ± 10; P < .001). Conclusion This study provides translational evidence that increased arterial stiffness might be associated with development and progression of HFpEF and may facilitate its early detection. Keywords: MR Functional Imaging, MR Imaging, Animal Studies, Cardiac, Aorta, Heart ClinicalTrials.gov identifier NCT03260621 Supplemental material is available for this article. © RSNA, 2024.